While regulators debate the legal status of cannabis-derived compound, CBD, Big Pharma attempts to corner the market. This post from TruthOut highlights how Big Pharma seeks to capitalize on the pain-reducing compounds derived from cannabis. The medicinal properties of cannabidiol (better known as CBD), a compound found in the Cannabis sativa L. plant species, are quickly ... Continue Reading